Wednesday, March 26, 2025
News published by Savara Inc. concerning MOLBREEVI for the potential treatment of aPAP, administered via an investigational eFlow® Technology nebulizer.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.
Thursday, January 30, 2025
News published by Savara Inc. concerning Molgramostim Nebulizer Solution, a novel investigational inhaled biologic, administered via an investigational eFlow® Technology nebulizer.
Wednesday, December 18, 2024
News published by Savara Inc. concerning MOLBREEVI for the potential treatment of aPAP, administered via an investigational eFlow® Technology nebulizer.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
Wednesday, June 26, 2024
News published by Savara Inc. concerning Molgramostim Nebulizer Solution, a novel investigational inhaled biologic, administered via an investigational eFlow® Technology nebulizer.
Tuesday, April 30, 2024
News published by Renovion Inc. concerning ARINA-1, a nebulized therapy administered via an optimized investigational eFlow® Technology nebulizer.
Tuesday, September 5, 2023
News published by Insmed presenting data from ARIKAYCE® (amikacin liposome inhalation suspension), administered via the optimized eFlow® Technology nebulizer Lamira®.
Tuesday, June 27, 2023
News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow® Technology nebulizer.
Tuesday, May 2, 2023
News published by Zambon concerning L-CsA-i, administered via an optimized investigational eFlow® Technology nebulizer.
Tuesday, April 18, 2023
News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow® Technology nebulizer.
Thursday, March 30, 2023
News published by Avalyn Pharma concerning AP02 (inhaled nintedanib), administered via an optimized eFlow® Technology nebulizer.
Thursday, March 30, 2023
News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow® Technology nebulizer.
Thursday, March 23, 2023
News published by Avalyn Pharma concerning AP01 (inhaled pirfenidone), administered via an optimized eFlow® Technology nebulizer.
Wednesday, March 15, 2023
News published by Recode Therapeutics concerning RCT1100, administered via an optimized investigational eFlow® Technology nebulizer.
Monday, January 09, 2023
News published by Spexis concerning murepavadin, administered via an optimized investigational eFlow® Technology nebulizer.
Wednesday, November 02, 2022
News published by Renovion Inc. concerning ARINA-1, administered via an optimized investigational eFlow® Technology nebulizer.
Thursday, August 25, 2022
News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow® Technology nebulizer.
Wednesday, August 03, 2022
News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow® Technology nebulizer.
Friday, June 17, 2022
News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow® Technology nebulizer.
Thursday, December 30, 2021
News published by Spexis concerning the closing of the merger of PARI’s partners Polyphor AG and EnBiotix Inc. and the change of name of the combined company to Spexis AG.
Tuesday, July 13, 2021
News published by Savara Inc. concerning molgramostim (inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)), administered via an optimized eFlow® Technology nebulizer.
Friday, June 25, 2021
Dr. Stefan Seemann will replace Dr. Martin Knoch as President of PARI Pharma GmbH on July 1, 2021.
Tuesday, May 25, 2021
News published by Avalyn Pharma concerning AP01 (a formulation of pirfenidone optimized for delivery via inhalation), administered via an optimized eFlow® Technology nebulizer.
Thursday, May 20, 2021
News published by Insmed presenting data from, among others, ARIKAYCE® (amikacin liposome inhalation suspension), administered via an optimized eFlow® Technology nebulizer.
Thursday, April 29, 2021
News published by Zambon, whose liposomal cyclosporine A for inhalation (L CsA i), which is in clinical development for the potential treatment of BOS, is administered via an optimized investigational eFlow® Technology nebulizer.
Tuesday, March 23, 2021
PARI Pharma GmbH announces the authorization of the LAMIRA Nebulizer System for delivery of Insmed’s drug product ARIKAYCE®
(amikacin liposome inhalation suspension) in Japan.
Monday, March 1, 2021
News published by Santhera Pharmaceuticals concerning Lonodelestat in cystic fibrosis, administered via an optimized eFlow® Technology nebulizer.
Thursday, January 7, 2021
News published by Insmed Incorporated concerning ARIKAYCE, administered using Lamira®, an optimized eFlow® Technology nebulizer.
Tuesday, December 22, 2020
News published by Polyphor concerning inhaled murepavadin, administered via an eFlow® Technology nebulizer.
Tuesday, November 24, 2020
News published by Polyphor concerning the development of inhaled murepavadin, administered via an eFlow® Technology nebulizer.
Thursday, October 29, 2020
PARI Pharma GmbH announces the issue of the CE declaration of conformity for its optimized eFlow Technology LAMIRA Nebuliser System.
Thursday, October 22, 2020
PARI Pharma’s proprietary aerosol delivery platform, eFlow Technology, continues its long track record of success with Aridis Pharmaceuticals.
Friday, October 16, 2020
News published by Avalyn Pharma concerning AP01 (a formulation of pirfenidone optimized for delivery via inhalation), administered via an optimized eFlow® Technology nebulizer.
Tuesday, October 13, 2020
News published by Ionis Pharmaceuticals concerning IONIS-ENAC-2.5 Rx, administered via an optimized eFlow® Technology nebulizer.
Friday, July 24, 2020
News published by Insmed Incorporated concerning ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, administered with Lamira®, an optimized eFlow® Technology nebulizer.
Tuesday, July 7, 2020
News published by Insmed Incorporated concerning ARIKAYCE® (amikacin liposome inhalation suspension), administered with Lamira®, an optimized eFlow® Technology nebulizer.
Thursday, June 18, 2020
News published by Renovion, Inc. concerning their lead therapeutic candidate ARINA-1, administered via an optimized eFlow® Technology nebulizer.
Monday, June 1, 2020
News published by Biomarck Pharmaceuticals concerning its novel anti-MARCKS peptide BIO-11006 in non-small cell lung cancer (NSCLC), administered via an optimized eFlow® Technology nebulizer.
Tuesday, April 28, 2020
The designation is for L CsA i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a Zambon company
News published by Zambon concerning L-CsA-i, administered via an optimized investigational eFlow® Technology nebulizer.
Thursday, February 20, 2020
News published by Breath Therapeutics concerning L-CsA-i, administered via an optimized investigational eFlow® Technology nebulizer.
Monday, December 16, 2019
News published by Kamada Ltd. concerning inhaled AAT, administered via an optimized investigational eFlow® Technology nebulizer.
Tuesday, September 10, 2019
News published by Santhera Pharmaceuticals concerning POL6014 in cystic fibrosis, administered with an optimized investigational eFlow® Technology nebulizer.
Thursday, July 25, 2019
News published by Zambon Pharma concerning the acquisition of biopharmaceutical company Breath Therapeutics
News published by Gimv concerning the sale of biopharmaceutical company Breath Therapeutics
News published by Sofinnova Partners concerning the sale of biopharmaceutical company Breath Therapeutics
Monday, May 20, 2019
News published by Insmed Incorporated concerning ARIKAYCE® (amikacin liposome inhalation suspension), administered with Lamira®, an optimized eFlow® Technology nebulizer.
Wednesday, May 1, 2019
News published by Sunovion Pharmaceuticals Inc. presenting data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019.
Tuesday, March 26, 2019
News published by Breath Therapeutics concerning L-CsA-I, administered via an optimized investigational eFlow® Technology nebulizer.
Tuesday, October 2, 2018
ARIKAYCE® is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options
Thursday, December 7, 2017
LONHALA MAGNAIR Inhalation Solution is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S.
Neiens, V., Hansbauer, EM., Jaquin, T.J. et al. (2025).
Nat Commun 16, 3251 (2025).
Montaño, C., Bendstrup, E., Rønnov-Jessen, I. et al.
ERJ Open Res 2025; 11: 00567-2024
Heine, B., Oelhaf, S., Braeunlich, G., Steinfuehrer, K. (2024).
Drug Delivery to the Lungs (DDL), Edinburgh, UK, Dec 2024.
Fuchs, C., Ram, R. (2024).
ONdrugDelivery, Issue 162 (June 2024), pp 16–20.
Bräunlich, G., Hahn, M. (2024).
ONdrugDelivery, Issue 158 (April 2024), pp 16–19.
Ringshausen, F.C., Shapiro, A.J., Nielsen, K.G., Mazurek, H., Pifferi, M., Donn, K.H. et al. (2023).
The Lancet Respiratory Medicine, Volume 12, Issue 1, P21-33, JANUARY 2024
Yanchao, L., Xu, C., Wenkang, W., Weigand, B. (2023).
Physics of Fluids 35, 063316 (2023)
Seder, R.A., Gagne, M., Flynn, B.J., Andrew, S.F. et al. (2023).
bioRxiv preprint, November 8, 2023
Streblow, D.N., Hirsch, A.J., Stanton, J.J. et al. (2023).
Nat Commun 14, 7062 (2023).
Heine, B., Hein, C., Njoya, A. & Seemann, S. (2023).
ISAM 2023, International Society for Aerosols in Medicine, Saarbrücken, Germany, August 26-30, 2023.
Mahri, S., Wilms, T., Hagedorm, P. et al. (2023).
European Journal of Pharmaceutical Sciences, Volume 189, 1 October 2023, 106522.
West, A., Chaudhuri, N., Barczyk, A. et al. (2023).
Thorax, Published Online First: 22 March 2023
Schwarz, C., Procaccianti, C., Costa, L., Brini, R., Friend, R., Caivano, G., Sadafi, H., Mussche, C., Schwenck, N., Hahn, M., Murgia, X. & Bianci, F. (2022).
International Journal of Molecular Sciences 2022, 23(17), 9597
Neurohr, C., Kneidinger, N., Ghiani, A., Monforte, V., Knoop, C., Jaksch, P., Parmar, J., Ussetti, P., Sole, A., Müller-Quernheim, J., Kessler, R., Wirtz, H., Boerner, G., Denk, O., Prante Fernandes, S. & Behr, J. (2022).
American Journal of Transplantation 2022;22:222–229.
Anderson, S., Atkins, P., Bäckman, P., Cipolla, D., Clark, A., Daviskas, E., Disse, B., Entcheva-Dimitrov, P., Fuller, R., Gonda, I., Lundbäck, H., Olsson, B. & Weers, J. (2022).
Pharmacological Reviews January 2022, 74 (1) 48-118.
Heine, B., Keller, J., Dietsche, J., Winzen, A., Schuschnig, U. & Seemann, S. (2022).
Respiratory Drug Delivery (RDD) 2022, Orlando, Florida, May 1-5, 2022 (in person), April 25-June 30, 2022 (virtual), Poster presentation
Schuschnig, U., Winzen, A., Heine, B., Schwenck, N. & Seemann, S. (2022).
Respiratory Drug Delivery (RDD) 2022, Orlando, Florida, May 1-5, 2022 (in person), April 25-June 30, 2022 (virtual), Poster presentation.
Winzen, A., Steinfuehrer, K., Schuschnig, U. & Seemann, S. (2022).
Respiratory Drug Delivery (RDD) 2022, Orlando, Florida, May 1-5, 2022 (in person), April 25-June 30, 2022 (virtual), Poster presentation.
Fuchs, C., Buchner, S. (2021).
ONdrugDelivery, Issue 128 (Dec 2021), pp 10–14.
Schwarz, C., Procaccianti, C., Mignot, B., Sadafi, H., Schwenck, N., Murgia, X. & Bianco, F. (2021).
Pharmaceutics 2021, 13(12).
Tashkin, D. P., Niu, X., Sharma, S. & Sanjar, S. (2021).
npj Primary Care Respiratory Medicine, volume 31, Article number: 43 (2021).
Wildman, M. J., O’Cathain, A., Maguire, C., Arden, M. A., Hutchings, M., Bradley, J., Walters, S. J., Whelan, P., Ainsworth, J., Buchan, I., Mandefield, L., Sutton, L., Tappenden, P., Elliott, R. A., Hoo, Z., H., Drabble, S. J., Beever, D. & CFHealthHub Study Team (2021).
Thorax Published Online First: 23 September 2021.
Moore, J. E., Millar, B. C., Ollman-Selinger, M. & Cambridge, L. (2021).
Respiratory Care September 2021, 66 (9) 1446-1457.
Li, Z., Perkins, W. & Cipolla, D. (2021).
European Journal of Pharmaceutics and Biopharmaceutics Volume 166, September 2021, Pages 10-18.
To synopsis of the publication
Arden, M. A., Hutchings, M., Whelan, P., Drabble, S. J., Beever, D., Bradley, J. M., Hind, D., Ainsworth, J., Maguire, C., Cantrill, H., O´Cathain, A. & Wildman, M. (2021).
Pilot and Feasibility Studies volume 7, Article number: 1 (2021).
Schuschnig, U., Heine, B. & Knoch, M. (2021)
Journal of Aerosol Medicine and Pulmonary Drug Delivery, Published Online: June 7, 2021.
Hanania, N. A., Yohannes, A. M., Ozol-Godfrey, A., Tocco, M., Goodin, Th., Sharma, S. & Sanjar, S. (2021).
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 865–875.
Trapnell, B. C., Inoue, Y., Bonella, F., Morgan, C., Jouneau, S., Bendstrup, E., Campo, I., Papiris, S.A., Yamaguchi, E., Cetinkaya, E., Ilkovich, M. M., Kramer, M. R., Veltkamp, M., Kreuter, M., Baba, T., Ganslandt, C., Tarnow, I., Waterer, G. & Jouhikainen, T. (2020).
New England Journal of Medicine 2020; 383:1635-1644.
Abd-Elaziz, K., Elberink, H. O. & Diamant, Z. (2020).
European Clinical Respiratory Journal 2020, VOL. 7, 1809083.
Stephenson, J.J., Dembek, C., Caldwell-Tarr, A., Conto, R.M., Paullin, M., Kerwin, E.M. (2020).
Int J Chron Obstruct Pulmon Dis. 2020 Jul 14;15:1713-1727. eCollection 2020.
Kaminskas, L. M., Landersdorfer, C. B., Bischof, R. J., Leong, N., Ibrahim, J., Davies, A. N., Pham, S., Beck, S., Montgomery, B., Surber, M. W. (2020).
Pharmaceutical Research, volume 37, Article number: 3 (2020).
Beck-Broichsitter, M. (2019).
Journal of Pharmaceutical Sciences 108 (2019) 2588-2592.
Khoo, J. K., Montgomery, A. B., Otto, K. L., Surber, M., Faggian, J., Lickliter, J. D., Glaspole, I. (2019).
Journal of aerosol medicine and pulmonary drug delivery, 32(0), 1-6.
Iacono, A., Wijesinha, M., Rajagopal, K., Murdock, N., Timofte, I., Griffith, B., Terrin, M. (2019).
ERJ Open Research 2019 5: 00167-2019.
Barth, P., Bruijnzeel, P., Wach, A., Sellier Kessler, O., Hooftman, L., Zimmermann, J., Naue, N., Huber, B., Heimbeck, I., Kappeler, D., Timmer, W., Chevalier, E. (2019).
Journal of Cystic Fibrosis.
Vonarburg, C., Loetscher, M., Spycher, M. O., Kropf, A., Illi, M., Salmon, S., Roberts, S., Steinfuehrer, K., Campbell, I., Koernig, S., Bain, J., Edler, M., Baumann, U., Miescher, S., Metzger, D. W., Schaub, A., Käsermann, F. & Zuercher, A. W. (2019).
Respiratory Research 2019.
Pham, S., Ferguson, G. T., Kerwin, E., Goodin, T., Wheeler, A., & Bauer, A. (2018).
Journal of aerosol medicine and pulmonary drug delivery, 31(3), 162-169.
Fuchs, C., & Koehler, Y. (2018).
ONdrugDelivery Publishing 2018, June 6th, 87, 66-70.
Fuchs, C., Brosig, M., Finke, M., Fiebig, D., Soni, P., Tutuncu, A., Saponjic, R., & Knoch, M. (2017).
European Respiratory Journal 2017, 50.
Sawicki, G. S., Chou, W., Raimundo, K., Trzaskoma, B., & Konstan, M. W. (2015).
Journal of Cystic Fibrosis, 14(6), 777-783.
Schuschnig, U., Seidler, A., Seemann, S., & Knoch, M. (2015).
20th International Congress of the International Society for Aerosols in Medicine (ISAM), Munich, Germany, May 30 to June 3, 2015.
Moeller, W., Schuschnig, U., Bartenstein, P., Meyer, G., Haeussinger, K., Schmid, O., & Becker, S. (2014).
Journal of aerosol medicine and pulmonary drug delivery, 27(4), 255-263.
Gallem, T. (2014).
ONdrugDelivery Publishing 2014, June 19th, 50,13-16 (ondrugdelivery.com).
Griese, M., Eismann, C., Börner, G., Denk, O., Schierholz, J. M., Keller, M., Mazurek, H., & Kappler, M. (2014).
Journal of aerosol medicine and pulmonary drug delivery, 27(3), 185-192.
Boerner, G., Prante, S., & Borella, F. (2014).
Journal of Cystic Fibrosis, 13, S121.
Möller, W., Schuschnig, U., Celik, G., Münzing, W., Bartenstein, P., Häussinger, K., Kreyling, W. G., Knoch, M., Canis, M., & Becker, S. (2013).
PloS one, 8(9), e74991.
Möller, W., Schuschnig, U., Becker, S., Saba, G. K., Münzing, W., Bartenstein, P., & Knoch, M. (2013).
Journal of aerosol medicine and pulmonary drug delivery, 26(4), 257-258.
Mundt, C., Sventitskiy, A., Cehelsky, J. E., Patters, A. B., Tservistas, M., Hahn, M. C., Juhl, G., DeVincenzo, J. P. (2012).
ISRN pediatrics, 2012.
Coates, A. L., Green, M., Leung, K., Chan, J., Ribeiro, N., Ratjen, F., & Charron, M. (2011).
Journal of aerosol medicine and pulmonary drug delivery, 24(3), 157-163.
Moller, W., Saba, G. K., Haussinger, K., Becker, S., Keller, M., & Schuschnig, U. (2011).
Rhinology, 2011.
Fuchs, C., Prante, S., Pokorski, R., Lim, H., Denk, O., Seemann, S., & Knoch, M. (2011).
Pediatric Pulmonology, 46(34), 418.
Möller, W., Schuschnig, U., Khadem Saba, G., Meyer, G., Junge-Hülsing, B., Keller, M., & Häussinger, K. (2010).
Otolaryngology - Head and Neck Surgery, 142(3), 382-388.
Behr, J., Zimmermann, G., Baumgartner, R., Leuchte, H., Neurohr, C., Brand, P., Herpich, C., Sommerer, K., Seitz, K., Menges, G., Tillmanns, S., Keller, M., & the Munich Lung Transplant Group (2009).
Journal of aerosol medicine and pulmonary drug delivery, 22(2), 121-130.
Tservistas, M., Hahn, M., DeVincenzo, J., Hetzer, U., Uhlig, M., Cehelsky, J., Walsh, E., Kreutzer, T., O`Connor, S., Knoch, M. (2009).
Drug Delivery to the Lungs - DDL20, Edinburgh, United Kingdom, December 9-11, 2009. Proceedings: 53-56.
Lass, J. S., Sant, A., & Knoch M. (2006).
Expert opinion on drug delivery, 3(5), 693-702.
Knoch, M., & Keller M. (2005).
Expert opinion on drug delivery, 2(2), 377-390.
© 2025 PARI GmbH Spezialisten für effektive Inhalation